CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair
- PMID: 15800615
- DOI: 10.1038/nature03404
CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair
Abstract
Inherited mutations in BRCA2 are associated with a predisposition to early-onset breast cancers. The underlying basis of tumorigenesis is thought to be linked to defects in DNA double-strand break repair by homologous recombination. Here we show that the carboxy-terminal region of BRCA2, which interacts directly with the essential recombination protein RAD51, contains a site (serine 3291; S3291) that is phosphorylated by cyclin-dependent kinases. Phosphorylation of S3291 is low in S phase when recombination is active, but increases as cells progress towards mitosis. This modification blocks C-terminal interactions between BRCA2 and RAD51. However, DNA damage overcomes cell cycle regulation by decreasing S3291 phosphorylation and stimulating interactions with RAD51. These results indicate that S3291 phosphorylation might provide a molecular switch to regulate RAD51 recombination activity, providing new insight into why BRCA2 C-terminal deletions lead to radiation sensitivity and cancer predisposition.
Similar articles
-
The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry.Curr Biol. 2009 Jul 14;19(13):1075-85. doi: 10.1016/j.cub.2009.05.057. Epub 2009 Jun 18. Curr Biol. 2009. PMID: 19540122 Free PMC article.
-
BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis.Cancer Res. 2005 May 15;65(10):4117-25. doi: 10.1158/0008-5472.CAN-04-3071. Cancer Res. 2005. PMID: 15899802
-
A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.Genes Dev. 2016 Dec 1;30(23):2581-2595. doi: 10.1101/gad.289439.116. Epub 2016 Dec 9. Genes Dev. 2016. PMID: 27941124 Free PMC article.
-
Therapeutic exploitation of tumor cell defects in homologous recombination.Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267. Anticancer Agents Med Chem. 2008. PMID: 18473729 Review.
-
BRCA2: a universal recombinase regulator.Oncogene. 2007 Dec 10;26(56):7720-30. doi: 10.1038/sj.onc.1210870. Oncogene. 2007. PMID: 18066084 Review.
Cited by
-
Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.Biol Proced Online. 2020 Oct 1;22:23. doi: 10.1186/s12575-020-00133-5. eCollection 2020. Biol Proced Online. 2020. PMID: 33013205 Free PMC article. Review.
-
The phospho-dependent role of BRCA2 on the maintenance of chromosome integrity.Cell Cycle. 2021 Apr;20(8):731-741. doi: 10.1080/15384101.2021.1892994. Epub 2021 Mar 10. Cell Cycle. 2021. PMID: 33691600 Free PMC article. Review.
-
Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing.Cancer Biol Ther. 2019;20(5):633-641. doi: 10.1080/15384047.2018.1550566. Epub 2019 Jan 13. Cancer Biol Ther. 2019. PMID: 30638113 Free PMC article.
-
DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells.J Biol Chem. 2011 Oct 14;286(41):35899-35905. doi: 10.1074/jbc.M111.267690. Epub 2011 Aug 30. J Biol Chem. 2011. PMID: 21878640 Free PMC article.
-
In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2.Br J Cancer. 2008 Oct 21;99(8):1302-6. doi: 10.1038/sj.bjc.6604644. Epub 2008 Sep 16. Br J Cancer. 2008. PMID: 18797466 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous